NCT00193219 Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer Status COMPLETED Phase PHASE2
NCT00193154 OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma Status COMPLETED Phase PHASE2
NCT00177307 Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer Status COMPLETED Phase PHASE2
NCT00165568 Using Positron Emission Tomography to Evaluate the Effects of Bevacizumab on Intra-tumoral Pharmacokinetics of 5-fluorouracil in Metastatic Colorectal Cancer Status COMPLETED Phase PHASE2
NCT00159432 Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer Status COMPLETED Phase PHASE2
NCT00150657 Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer Status UNKNOWN Phase PHASE2
NCT00142480 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Status COMPLETED Phase PHASE2
NCT00142467 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma Status COMPLETED Phase PHASE2
NCT00140556 Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer Status COMPLETED Phase EARLY_PHASE1
NCT00139360 Efficacy of Bevacizumab Monotherapy in Treatment of Metastatic Melanoma Status COMPLETED Phase PHASE2
NCT00137826 Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma Status COMPLETED Phase PHASE2
NCT00137774 Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors Status COMPLETED Phase PHASE2
NCT00130728 A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer Status COMPLETED Phase PHASE3
NCT00127036 Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) Status TERMINATED Phase PHASE2
NCT00126633 Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer Status COMPLETED Phase PHASE2
NCT00126542 Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Status COMPLETED Phase PHASE2